Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Melasma is a common skin condition that causes patches of darker skin to form, often on the face. It tends to occur in areas with more sun exposure. Melasma is not harmful, but it may affect how a ...

Pimple patches have revolutionized the approach to acne treatment, emerging as the darling of social media skincare enthusiasts and dermatology offices alike. These unassuming adhesives have ...

Not much has been easy for Agoura Hills-based Acelyrin since going public on May 4 with shares plummeting 88% since its IPO and so far, even a potential merger the company had lined up has become ...

When it comes to skin care, there aren’t a lot of quick fixes. Thankfully, under-eye patches are one of the outliers. These mini treatments can help your eyes look more awake and youthful in ...

Investing.com -- Shares of ACELYRIN, INC. (Nasdaq: SLRN) soared 16% following the company’s confirmation of an unsolicited buyout proposal from Concentra Biosciences. The late-stage clinical biopharma ...

(Il Sole 24 Ore Radiocor) - Milano, 21 feb - Shares in US biopharma company Acelyrin jumped in morning trade after it said it had received an unsolicited indication of interest from Concentra ...

Con­cen­tra Bio­sciences, the shell com­pa­ny from Tang Cap­i­tal that tries to buy out strug­gling biotechs, has found an­oth­er tar­get, this time try­ing to throw a … ...

Shares of Acelyrin, Inc. (NASDAQ: SLRN) increased 12.44% to $2.44 on Thursday after an equity-related development was confirmed. An unsolicited takeover offer from Concentra Biosciences, LLC, a ...

Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 ...